Myelination, oligodendrocytes, and serious mental illness

GLIA

Volumn 62, Issue 11, 2014, Pages 1856-1877

  Haroutunian, V ^a,b   Katsel, P ^a   Roussos, P ^a,b   Davis, K L ^a   Altshuler, L L ^c,d,e   Bartzokis, G ^c,d,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Apolipoprotein; Astrocyte; Degeneration; GSK 3; Metabolic; Microglia; MRI; RAS; White matter

Indexed keywords

ANGIOTENSIN; ATYPICAL ANTIPSYCHOTIC AGENT; GLYCOGEN SYNTHASE KINASE 3; INSULIN; LITHIUM; MYELIN; NEUROTRANSMITTER; VALPROIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AGING; ALZHEIMER DISEASE; ASTROCYTE; BIPOLAR DISORDER; BRAIN CELL; BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN METABOLISM; DEMENTIA; DEMYELINATING DISEASE; DISEASE SEVERITY; FUNCTIONAL NEUROIMAGING; GLIA; GRAY MATTER; HOMEOSTASIS; HUMAN; INFLAMMATION; LIPID METABOLISM; MENTAL DISEASE; MICROGLIA; MOOD DISORDER; MYELINATION; NERVE CELL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PHENOTYPE; RANVIER NODE; REMYELINIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCHIZOPHRENIA; SYSTEMS BIOLOGY; WHITE MATTER; BRAIN; METABOLISM; MYELIN SHEATH; PATHOLOGY;

AGING; BRAIN; HUMANS; MENTAL DISORDERS; MYELIN SHEATH; NEUROTRANSMITTER AGENTS; OLIGODENDROGLIA;

EID: 84912565425     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22716     Document Type: Review

References (96)

1. Allen NJ, Barres BA. 2009. Neuroscience: Glia-more than just brain glue. Nature 457:675-677.
2. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. 2011. Microinfarct pathology, dementia, and cognitive systems. Stroke 42:722-727.
3. Bartzokis G. 2011a. Alzheimer's disease as homeostatic responses to agerelated myelin breakdown. Neurobiol Aging 32:1341-1371.
4. Bartzokis G. 2011b. Neuroglialpharmacology: White matter pathophysiologies and psychiatric treatments. Front Biosci 16:2695-2733.
5. Bartzokis G. 2012. Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 62:2137- 2153.
6. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. 2001. Age-related changes in frontal and temporal lobe volumes in men: A magnetic resonance imaging study. Arch Gen Psychiatry 58:461-465.
7. Bartzokis G, Lu PH. 2013. Degenerative brain diseases and white matter injury. In: Baltan S, Carmichael ST, Malute C, Xi G, Zhang JH, editors. White matter injury in stroke and CNS diseases. New York: Springer 281-305.
8. Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL. 2006. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: Implications for cognitive decline and dementia. Arch Gen Psychiatry 63:63-72.
9. Bartzokis G, Lu PH, Heydari P, Couvrette A, Lee GJ, Kalashyan G, Freeman F, Grinstead JW, Villablanca P, Finn JP, Mintz J, Alger JR, Altshuler LL. 2012a. Multimodal MRI assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol Psychiatry 72:1026-1034.
10. Bartzokis G, Lu PH, Raven EP, Amar CP, DeTore NR, Couvrette AJ, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH. 2012b. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophrenia Res 140: 122-128.
11. Bartzokis G, Lu PH, Stewart SB, Oluwadara B, Lucas AJ, Pantages J, Pratt E, Sherin JE, Altshuler LL, Mintz J, Oluwadara B, Pantages J, Pratt E, Sherin JE, Stewart SB. 2009. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res 113:322-331.
12. Buzsaki G, Draguhn A. 2004. Neuronal oscillations in cortical networks. Science 304:1926-1929.
13. Chew LJ, Fusar-Poli P, Schmitz T. 2013. Oligodendroglial alterations and the role of microglia in white matter injury: Relevance to schizophrenia. Dev Neurosci 35:102-129.
14. Crawford AH, Chambers C, Franklin RJ. 2013. Remyelination: The true regeneration of the central nervous system. J Comp Pathol 149:242-254.
15. de Kloet AD, Krause EG, Woods SC. 2010. The renin angiotensin system and the metabolic syndrome. Physiol Behav 100:525-534.
16. De Peri L, Crescini A, Deste G, Fusar-Poli P, Sacchetti E, Vita A. 2012. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: A meta-analysis of controlled magnetic resonance imaging studies. Curr Pharm Des 18:486-494.
17. De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, Jope RS. 2008. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 181:338-345.
18. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C. 2011. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77:461-468.
19. Dimou L, Gotz M. 2012. Shaping barrels: Activity moves NG21 glia. Nat Neurosci 15:1176-1178.
20. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. 2006. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in schizophrenia. Neurobiol Dis 79: 531-540.
21. Emsell L, Langan C, Van Hecke W, Barker GJ, Leemans A, Sunaert S, McCarthy P, Nolan R, Cannon DM, McDonald C. 2013. White matter differences in euthymic bipolar I disorder: A combined magnetic resonance imaging and diffusion tensor imaging voxel-based study. Bipolar Disord 15: 365-376.
22. Ferrarelli F, Sarasso S, Guller Y, Riedner BA, Peterson MJ, Bellesi M, Massimini M, Postle BR, Tononi G. 2012. Reduced natural oscillatory frequency of frontal thalamocortical circuits in schizophrenia. Arch Gen Psychiatry 69:766-774.
23. Foong J, Symms MR, Barker GJ, Maier M, Woermann FG, Miller DH, Ron MA. 2001. Neuropathological abnormalities in schizophrenia: Evidence from magnetization transfer imaging. Brain 124 (Part 5):882-892.
24. Franklin RJM, ffrench-Constant C. 2008. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci 9:839-855.
25. Friston KJ. 1998. The disconnection hypothesis. Schizophr Res 30:115-125.
26. Grydeland H, Walhovd KB, Tamnes CK, Westlye LT, Fjell AM. 2013. Intracortical myelin links with performance variability across the human lifespan: Results from T1- and T2-weighted MRI myelin mapping and diffusion tensor imaging. J Neurosci 33:18618-18630.
27. Hagmann P, Sporns O, Madan N, Cammoun L, Pienaar R, Wedeen VJ, Meuli R, Thiran JP, Grant PE. 2010. White matter maturation reshapes structural connectivity in the late developing human brain. Proc Natl Acad Sci USA 107:19067-19072.
28. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. 2012. Brain volumes in schizophrenia: A meta-analysis in over 18 000 subjects. Schizophr Bull 39:1129-1138.
29. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98:4746-4751.
30. Haroutunian V, Dracheva S, Davis K, Katsel P. 2008. Oligodendroglial and myelin deficits in chronic schizophrenia: Implications for saltatory signal conduction and the disconnectivity syndrome. Int J Neuropsychopharmacol 11:22-23.
31. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V. 2009. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72:1720-1726.
32. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, Lieberman J, Hamilton SP, Sullivan P, Sklar P, Purcell S, Smoller JW. 2010. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 167:1254-1263.
33. Hulshoff Pol HE, van Baal GC, Schnack HG, Brans RG, van der Schot AC, Brouwer RM, van Haren NE, Lepage C, Collins DL, Evans AC, Boomsma DI, Nolen W, Kahn RS. 2012. Overlapping and segregating structural brain abnormalities in twins with schizophrenia or bipolar disorder. Arch Gen Psychiatry 69:349-359.
34. Insel TR. 2010. Rethinking schizophrenia. Nature 468:187-193.
35. Insel TR. 2012. Next-generation treatments for mental disorders. Sci Transl Med 4:155ps19.
36. Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ. 2008. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. J Immunol 181: 8077-8087.
37. Johnson ES, Ludwin SK. 1981. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol 53:93-98.
38. Jope RS, Johnson GV. 2004. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95-102.
39. Karoutzou G, Emrich HM, Dietrich DE. 2008. The myelin-pathogenesis puzzle in schizophrenia: A literature review. Mol Psychiatry 13:245-260.
40. Katsel P, Davis KL, Gorman JM, Haroutunian V. 2005a. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizo Res 77:241-252.
41. Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V. 2013. Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection aganist oxidative stress in Alzheimer's disease. PloS One 8:e68361.
42. Kim JH, Renden R, von Gersdorff H. 2013. Dysmyelination of auditory afferent axons increases the jitter of action potential timing during high-frequency firing. J Neurosci 33:9402-9407.
43. Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, Snider WD. 2009. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 12:1390-1397.
44. Kreczmanski P, Heinsen H, Mantua V, Woltersdorf F, Masson T, Ulfig N, Schmidt-Kastner R, Korr H, Steinbusch HW, Hof PR, Schmitz C. 2009. Microvessel length density, total length, and length per neuron in five subcortical regions in schizophrenia. Acta Neuropathol 117:409-421.
45. Krstic D, Knuesel I. 2013. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 9:25-34.
46. Kubicki M, McCarley R, Westin CF, Park HJ, Maier S, Kikinis R, Jolesz FA, Shenton ME. 2007. A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res 41:15-30.
47. Maioli S, Bavner A, Ali Z, Heverin M, Ismail MA, Puerta E, Olin M, Saeed A, Shafaati M, Parini P, Cedazo-Minguez A, Bjorkhem I. 2013. Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain? PLoS One 8:e68534.
48. Marner L, Nyengaard JR, Tang Y, Pakkenberg B. 2003. Marked loss of myelinated nerve fibers in the human brain with age. J Comp Neurol 462: 144-152.
49. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, Maccarrone G, Turck CW, Dias-Neto E. 2009b. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116:275-289.
50. Masquelier T, Hugues E, Deco G, Thorpe SJ. 2009. Oscillations, phase-offiring coding, and spike timing-dependent plasticity: An efficient learning scheme. J Neurosci 29:13484-13493.
51. Matute C, Alberdi E, Domercq M, Sanchez-Gomez MV, Perez-Samartin A, Rodriguez-Antiguedad A, Perez-Cerda F. 2007. Excitotoxic damage to white matter. J Anat 210:693-702.
52. Matute C, Domercq M, Sanchez-Gomez MV. 2006. Glutamate-mediated glial injury: Mechanisms and clinical importance. Glia 53:212-214.
53. McTigue DM, Tripathi RB. 2008. The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 107:1-19.
54. Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR, Berman KF. 2005. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 62:379-386.
55. Miller DJ, Duka T, Stimpson CD, Schapiro SJ, Baze WB, McArthur MJ, Fobbs AJ, Sousa AM, Sestan N, Wildman DE, Lipovich L, Kuzawa CW, Hof PR, Sherwood CC. 2012. Prolonged myelination in human neocortical evolution. Proc Natl Acad Sci USA 109:16480-16485.
56. Morrison BM, Lee Y, Rothstein JD. 2013. Oligodendroglia: metabolic supporters of axons. Trends Cell Biol 23:644-651.
57. Mosebach J, Keilhoff G, Gos T, Schiltz K, Schoeneck L, Dobrowolny H, Mawrin C, Muller S, Schroeter ML, Bernstein HG, Bogerts B, Steiner J. 2013. Increased nuclear Olig1-expression in the pregenual anterior cingulate white matter of patients with major depression: A regenerative attempt to compensate oligodendrocyte loss? J Psychiatr Res 47:1069-1079.
58. Nave KA. 2010. Myelination and support of axonal integrity by glia. Nature 468:244-252.
59. Nave KA, Trapp BD. 2008. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 31:535-561.
60. Neumann H, Kotter MR, Franklin RJ. 2008. Debris clearance by microglia: An essential link between degeneration and regeneration. Brain 132:288-295.
61. Norkute A, Hieble A, Braun A, Johann S, Clarner T, Baumgartner W, Beyer C, Kipp M. 2009. Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus. J Neurosci Res 87:1343-1355.
62. O'Kusky J, Ye P. 2012. Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol 33:230-251.
63. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. 2011. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 70:88-96.
64. Peirce TR, Bray NJ, Williams N, Haroutunian V, Buxbaum J, Buckland P, Owen M, O'Donovan M. 2004. Convergent functional genomics, association and linkage analysis suggests 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) as a potential susceptibility gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 130B:81.
65. Peirce TR, Bray NJ, Williams N, Norton N, Moskivina V, Preece A, Haroutunian V, Buxbaum J, Owen M, O'Donovan MC. 2006. Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 63: 18-24.
66. Penfield W, Cone W. 1928. Acute swelling of oligodendroglia: A specific type of neuroglia change. Arch Neurol Psychiatry 16:131-153.
67. Petanjek Z, Judas M, Simic G, Rasin MR, Uylings HB, Rakic P, Kostovic I. 2012. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc Natl Acad Sci USA 108:13281-13286.
68. Peters A. 2009. The effects of normal aging on myelinated nerve fibers in monkey central nervous system. Front Neuroanat 3:10.
69. Peters A, Kemper T. 2012. A review of the structural alterations in the cerebral hemispheres of the aging rhesus monkey. Neurobiol Aging 33:2357- 2372.
70. Peters A, Sethares C. 2004. Oligodendrocytes, their progenitors and other neuroglial cells in the aging primate cerebral cortex. Cereb Cortex 14:995- 1007.
71. Peters A, Sethares C, Moss MB. 2010. How the primate fornix is affected by age. J Comp Neurol 518:3962-3980.
72. Poirier J. 2008. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimers Dement 4(1, Suppl 1):S91-S97.
73. Poliak S, Peles E. 2003. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 4:968-980.
74. Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, Sweatt JD, McMahon L, Bartolucci AA, Li X, Jope RS. 2010. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35:1761-1774.
75. Ren Y, Wang H, Xiao L. 2013. Improving myelin/oligodendrocyte-related dysfunction: A new mechanism of antipsychotics in the treatment of schizophrenia? Int J Neuropsychopharmacol 16:691-700.
76. Rietkerk T, Boks MP, Sommer IE, de Jong S, Kahn RS, Ophoff RA. 2009. Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. Mol Psychiatry 14:353-355.
77. Rinholm JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, Attwell D. 2011. Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci 31:538-548.
78. Roussos P, Katsel P, Davis KL, Siever LJ, Haroutunian V. 2012a. A system level transcriptomic analysis in schizophrenia postmortem brain. Arch Gen Psychiatry 69:1205-1213.
79. Roussos P, Katsel P, Siever L, Davis KL, Haroutunian V. 2012b. Molecular and genetic evidence for abnormalities in the nodes of Ravier in schizophrenia. Arch Gen Psychiatry 69:7-15.
80. Scherer SS, Arroyo EJ, Peles E, Lazzarini RA. 2004. Functional organization of the nodes of Ranvier. Myelin biology and disorders 1. San Diego, California: Elsevier. pp 89-116.
81. Schoenemann PT, Sheehan MJ, Glotzer LD. 2005. Prefrontal white matter volume is disproportionately larger in humans than in other primates. Nat Neurosci 8:242-252.
82. Shackleford G, Makoukji J, Grenier J, Liere P, Meffre D, Massaad C. 2013. Differential regulation of Wnt/beta-catenin signaling by liver X receptors in schwann cells and oligodendrocytes. Biochem Pharmacol 86:106-114.
83. Simon B, Schmidt S, Lukas C, Gieseke J, Traber F, Knol DL, Willinek WA, Geurts JJ, Schild HH, Barkhof F, Wattjes MP. 2010. Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3Tesla. Eur Radiol 20:1675-1683.
84. Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI, Ripke S, Santangelo S, Sullivan PF. 2013. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381:1371-1379.
85. Sokolov BP. 2006. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol 10:547-555.
86. Susuki K, Rasband MN. 2008. Molecular mechanisms of node of Ranvier formation. Curr Opin Cell Biol 20:616-623.
87. Torkildsen O, Brunborg LA, Myhr KM, Bo L. 2008. The cuprizone model for demyelination. Acta Neurol Scand Suppl 188:72-76.
88. Uranova NA, Vikhreva OV, Rachmanova VI, Orlovskaya DD. 2011a. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: A postmortem morphometric study. Schizophr Res Treatment 2011:13.
89. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. 2004b. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley neuropathology consortium. Schizophr Res 67:269-275.
90. Vigano F, Mobius W, Gotz M, Dimou L. 2013. Transplantation reveals regional differences in oligodendrocyte differentiation in the adult brain. Nat Neurosci 16:1370-1372.
91. Vostrikov V, Uranova N. 2011. Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr Res Treatment 2011:10.
92. Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S. Smith R.L. Green E. Grozeva D. Holmans P. Owen M.J. O'Donovan M.C. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Genet 20 2011 387-391.
93. Yakovlev PI, Lecours AR. 1967. The myelogenetic cycles of regional maturation of the brain. In: Minkowski A, editor. Regional Development of the Brain in Early Life. Oxford: Blackwell Scientific Publications. pp 3-70.
94. Zhang K, Sejnowski TJ. 2000. A universal scaling law between gray matter and white matter of cerebral cortex. Proc Natl Acad Sci USA 97:5621- 5626.
95. Zhuang L, Sachdev PS, Trollor JN, Reppermund S, Kochan NA, Brodaty H, Wen W. 2013. Microstructural white matter changes, not hippocampal atrophy, detect early amnestic mild cognitive impairment. PLoS One 8: e58887.
96. Zonta B, Tait S, Melrose S, Anderson H, Harroch S, Higginson J, Sherman DL, Brophy PJ. 2010. Glial and neuronal isoforms of Neurofascin have distinct roles in the assembly of nodes of Ranvier in the central nervous system. J Cell Biol 181:1169-1177.